Drägerwerk stock falls 2.09 percent as Q2 margins improve

Drägerwerk stock posted Q2 revenue of EUR 847.3 million, up 8.5 percent currency adjusted. The EBIT margin reached 5.4 percent after 2.6 percent a year earlier.

Drägerwerk stock fell 2.09 percent to EUR 122.00 on Xetra on September 24, 2026 at 5:35 p.m. CET, putting it 2.24 percent below the 52-week high of EUR 124.80. The move came as the company's latest operating figures showed a sharper margin profile.

Q2 revenue reaches EUR 847.3 million

In Q2 2026, Drägerwerk generated revenue of EUR 847.3 million, an increase of 8.5 percent on a currency-adjusted basis, according to Börse Online in its September 10, 2026 report. The figure gives the medical and safety technology group a stronger base for the second half of the year.

The EBIT margin reached 5.4 percent, compared with 2.6 percent in the prior-year quarter, the same report said. That 2.8 percentage-point improvement matters because it shows that revenue growth is translating into operating leverage rather than relying only on higher sales volumes.

2026 margin guidance stays wide

Drägerwerk's investor-relations page lists currency-adjusted revenue growth guidance of 2.0 to 6.0 percent for 2026 and an EBIT margin range of 5.0 to 7.5 percent. The guidance also includes a gross-margin range of 44.0 to 46.0 percent, according to the company's investor-relations page.

The upper and lower ends of that margin corridor leave execution as the central valuation variable. Q2's 5.4 percent margin sits above the guidance floor by 0.4 percentage points, while the 2026 revenue range still spans 4.0 percentage points from low to high.

Stock remains near yearly high

At EUR 122.00, the shares remained 2.24 percent below the 52-week high of EUR 124.80 and well above the 52-week low of EUR 62.50 on September 24, 2026. The market capitalization was EUR 2.28872 billion, with 22,883 shares traded in the session.

The latest price action puts the stock close to its annual peak even after the daily decline. For investors, the key numerical test is whether the improved 5.4 percent quarterly EBIT margin can move toward the upper half of the company's 5.0 to 7.5 percent full-year corridor.

Drägerwerk stock data

• Company: Drägerwerk AG & Co. KGaA
• Ticker: DRW3
• Trading venue: Xetra
• Price (as of September 24, 2026, 5:35 p.m. CET): EUR 122.00
• Market capitalization: EUR 2.28872 billion (as of September 24, 2026)
• 52-week range: EUR 62.50-124.80 (as of September 24, 2026)
• Sector / Industry: Healthcare / Medical Devices
• Index membership: TecDAX and SDAX